BeiGene to Announce Fourth Quarter and Full Year 2024 Financial Results on February 27
BeiGene (NASDAQ: ONC) has scheduled the release of its fourth quarter and full year 2024 financial results for Thursday, February 27, 2025, before market open. The company, which plans to change its name to BeOne Medicines, will host a live webcast with management at 8:00 a.m. ET following the financial release.
Investors can access the webcast through BeiGene's investor relations websites. Participants are advised to register 15 minutes before the scheduled start time to ensure proper connection. An archived version of the webcast will be made available on the company's website afterward.
BeiGene (NASDAQ: ONC) ha programmato la pubblicazione dei suoi risultati finanziari del quarto trimestre e dell'intero anno 2024 per giovedì 27 febbraio 2025, prima dell'apertura del mercato. L'azienda, che prevede di cambiare nome in BeOne Medicines, ospiterà una diretta web con il management alle 8:00 a.m. ET subito dopo la pubblicazione finanziaria.
Gli investitori possono accedere alla diretta web tramite i siti web delle relazioni con gli investitori di BeiGene. Si consiglia ai partecipanti di registrarsi 15 minuti prima dell'orario di inizio programmato per garantire una connessione adeguata. Una versione archiviata della diretta sarà resa disponibile sul sito web dell'azienda successivamente.
BeiGene (NASDAQ: ONC) ha programado la publicación de sus resultados financieros del cuarto trimestre y del año completo 2024 para el jueves 27 de febrero de 2025, antes de la apertura del mercado. La empresa, que planea cambiar su nombre a BeOne Medicines, llevará a cabo una transmisión en vivo con la dirección a las 8:00 a.m. ET después de la publicación financiera.
Los inversores pueden acceder a la transmisión a través de los sitios web de relaciones con inversores de BeiGene. Se aconseja a los participantes registrarse 15 minutos antes de la hora de inicio programada para asegurar una conexión adecuada. Una versión archivada de la transmisión estará disponible en el sitio web de la empresa posteriormente.
BeiGene (NASDAQ: ONC)는 2024년 4분기 및 연간 재무 결과를 2025년 2월 27일 목요일, 시장 개장 전에 발표할 예정입니다. BeOne Medicines로 이름을 변경할 계획인 이 회사는 재무 발표 후 오전 8:00 ET에 경영진과의 라이브 웹캐스트를 진행합니다.
투자자는 BeiGene의 투자자 관계 웹사이트를 통해 웹캐스트에 접속할 수 있습니다. 참가자는 적절한 연결을 보장하기 위해 예정된 시작 시간 15분 전에 등록하는 것이 좋습니다. 웹캐스트의 아카이브 버전은 이후 회사 웹사이트에서 제공될 예정입니다.
BeiGene (NASDAQ: ONC) a prévu la publication de ses résultats financiers du quatrième trimestre et de l'année complète 2024 pour le jeudi 27 février 2025, avant l'ouverture des marchés. L'entreprise, qui envisage de changer son nom en BeOne Medicines, organisera un webinaire en direct avec la direction à 8h00 ET après la publication financière.
Les investisseurs peuvent accéder au webinaire via les sites de relations investisseurs de BeiGene. Les participants sont invités à s'inscrire 15 minutes avant l'heure de début prévue pour garantir une connexion adéquate. Une version archivée du webinaire sera disponible sur le site web de l'entreprise par la suite.
BeiGene (NASDAQ: ONC) hat die Veröffentlichung seiner Finanzergebnisse für das vierte Quartal und das gesamte Jahr 2024 für Donnerstag, den 27. Februar 2025, vor der Markteröffnung angesetzt. Das Unternehmen, das plant, seinen Namen in BeOne Medicines zu ändern, wird nach der Finanzveröffentlichung um 8:00 Uhr ET eine Live-Webcast mit dem Management veranstalten.
Investoren können über die Investor-Relations-Websites von BeiGene auf den Webcast zugreifen. Den Teilnehmern wird geraten, sich 15 Minuten vor der geplanten Startzeit zu registrieren, um eine ordnungsgemäße Verbindung sicherzustellen. Eine archivierte Version des Webcasts wird anschließend auf der Unternehmenswebsite verfügbar sein.
- None.
- None.
The conference call will be webcast live and a link to the webcast can be accessed from the investors section of BeiGene’s website at http://ir.beigene.com/, https://hkexir.beigene.com/, https://sseir.beigene.com/. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the company's website.
About BeiGene
BeiGene, which plans to change its name to BeOne Medicines, is a global oncology company that is discovering and developing innovative treatments that are more accessible and affordable to cancer patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them. Our growing global team of nearly 11,000 colleagues spans five continents. To learn more about BeiGene, please visit www.beigene.com and follow us on LinkedIn, X (formerly known as Twitter), Facebook and Instagram.
Forward-Looking Statements
This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeiGene's plans, commitments, aspirations and goals related to BeiGene’s medicines and drug candidates. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors which are discussed in the section entitled “Risk Factors” in BeiGene’s most recent periodic report filed with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20250213264583/en/
Investors:
Liza Heapes
+1 857-302-5663
ir@beigene.com
Media:
Kyle Blankenship
+1 667-351-5176
media@beigene.com
Source: BeiGene, Ltd.
FAQ
When will BeiGene (ONC) release its Q4 and FY 2024 earnings?
What time is BeiGene's (ONC) Q4 2024 earnings call?
What is BeiGene's (ONC) new company name?
How can investors access BeiGene's (ONC) Q4 2024 earnings webcast?
